Compare GCT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | NVAX |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | GCT | NVAX |
|---|---|---|
| Price | $39.33 | $9.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $33.00 | $11.33 |
| AVG Volume (30 Days) | 748.0K | ★ 4.1M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.70 | ★ 309.76 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,161,042,000.00 | $1,123,479,000.00 |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | $38.91 | ★ N/A |
| Revenue Growth | ★ 64.96 | 64.69 |
| 52 Week Low | $16.25 | $6.20 |
| 52 Week High | $51.82 | $11.85 |
| Indicator | GCT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 58.07 |
| Support Level | $38.42 | $9.14 |
| Resistance Level | $44.01 | $10.42 |
| Average True Range (ATR) | 2.77 | 0.59 |
| MACD | -0.79 | 0.22 |
| Stochastic Oscillator | 1.38 | 53.45 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.